Neuroendocrine Tumors Treatment Market Forecasts up to 2024, Research Report - Coherent Market Insights

As the name suggests (Neuro= nervous, endocrinal= hormonal), neuroendocrine tumors occur when there is an abnormal and excessive growth in tissues or neoplasm in neuroendocrine cells. These cells work as a bridge between the nervous and the endocrinal system. They receive the signal (neurotransmitters) from the neurons (nerve cells) and accordingly produce the relevant hormone. Thus, these cells are responsible for basic day-to-day functions such as eating behavior, metabolism, and reproduction. Neuroendocrine tumors can be benign or carcinogenic and can affect any part of the body. There are numerous kinds of neuroendocrine tumors; however, they are considered as a group of tissue since the cells of these tumors have common characteristics such as they look similar, they have unique secretory granules, and they generate polypeptide hormones and biogenic amines frequently.

Neuroendocrine Tumors Treatment Market Overview

According to a study conducted by the U.S. National Library of Medicine and American Cancer Society, the proportion of occurrence of neuroendocrine tumor increased from 2.48 to 5.86 during 2009–2010, in a population sample size of 1 lakh, (roughly 136% jump). According to the same study, the increase in number of neuroendocrine tumors may be a result of increased detection. The occurrences of neuroendocrine tumors have increased manifold over last 15 years. Owing to technological developments as well as early detection techniques, the 5-year survival rate of neuroendocrine tumors has increased in recent years. Consequently, the proportion of the population with neuroendocrine tumors opting for treatment have risen, given its high success rate. This is projected drive growth of the neuroendocrine tumor treatment market in the near future.

View the full report @

Neuroendocrine Tumors Treatment Market Taxonomy

On the basis anatomic distribution, neuroendocrine tumors treatment market is classified into:

    • Pituitary
    • Pulmonary
    • Thyroid
    • Gastroenteropancreatic
    • Others

On the basis of treatment, the global neuroendocrine tumors treatment market is classified into:

    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • Ostreotide
    • Targeted Therapy
    • Lutate
    • Others

On the basis of type of end user, the global neuroendocrine tumors treatment market is classified into:

    • Hospitals
    • Others

As per the World Health Organization, neuroendocrine tumors have been classified into three broad categories. They are well-differentiated neuroendocrine tumors, well-differentiated (low grade) neuroendocrine carcinomas, and poorly differentiated (high grade) neuroendocrine carcinomas. According to a report by National Center for Biotechnology Information (NCBI), neuroendocrine tumors are second-most prevalent gastrointestinal tumors in the U.S. However, pancreatic neuroendocrine tumor is the most common type of neuroendocrine tumor in the Asia Pacific region. As per Expert Rev Endocrinal Matlab, localized neuroendocrine tumors have grown many folds in the last two decades. Additionally, Surveillance, Epidemiology, and End Results (SEER) program survey data suggests that the incidence of malignant neuroendocrine tumors is increasing.

Ask for free sample report @

Technological advancements and early detection increasing revenue potential of neuroendocrine tumors market

Early detection is key to survival for neuroendocrine tumor. The survival rate as well as survival duration in patients diagnosed in Stage I are much more than patients who are diagnosed late. Moreover, latest advancements such as radiation therapy under which, targeted radiation therapy and external beam radiation therapy are highly effective when compared to usual medication. This have significantly increased effectiveness of neuroendocrine tumors treatment and diagnosis. Increasing awareness about effective treatment option for the ailment is another factor that would drive market growth in the future. Globally, patients and doctors alike have become more conscious about their health and economic burden of medical conditions have risen substantially. Earlier, medical checkups were a rare phenomenon. However, in the present global scenario, the percentage of medical checkups have increased significantly, which creates a favorable environment for growth of the neuroendocrine tumors treatment market. As the number of diagnosed patient increases, the rate of survival increases proportionally, this in turn will help in the growth of neuroendocrine tumors market over the forecast period (2016–2024).

Lutate emerging as a preferred drug in the Neuroendocrine Tumors Treatment Market

Hospitals remain the most potential avenue for investment for neuroendocrine tumors treatment market. The treatment needs critical care and strict supervision by the physician, which makes treatment in other facilities fairly tough. Moreover, surgeries are the most common treatment for neuroendocrine tumors, especially in the latter stages. Therefore, patients diagnosed with neuroendocrine tumors invariably choose hospitals for their treatment. However, apart from surgery, lutate is gaining prominence in the neuroendocrine treatment market. This is a new form of treatment that can be used if surgery, chemotherapy, radiation therapy proves to be ineffective. Lutate is the name of a drug that works by using radioactive particles and internally targets the infected cells/ tissue.

Major Players in the Neuroendocrine Tumors Treatment Market

Some of the companies that manufacture Lutate are Advanced Accelerator Applications and Lutate SL. Other major players in the neuroendocrine tumors treatment market include F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Ltd., Eli Lilly & Company, Amgen, Inc., Ispen SA, Callisto Pharmaceuticals Pvt. Ltd., Bristol-Myers Squibb, Teva Pharmaceuticals, Ltd. and Biosynthema,


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.



Mr. Shah

1001 4th Ave, #3200

Seattle, WA 98154

Tel No: (+1)206-701-6702

Visit Blog: